Clinical Trials Logo

Clinical Trial Summary

Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.


Clinical Trial Description

This is a prospective, double-blind, placebo controlled, clinical trial examining vascular effects of allopurinol in patients who received a kidney transplant that are maintaining stable renal function for at least 1 year. End-points include pulse-wave velocity, systemic blood pressure and kidney function among others. ;


Study Design


Related Conditions & MeSH terms

  • Complications of Renal Transplant

NCT number NCT01332799
Study type Interventional
Source University of Iowa
Contact
Status Terminated
Phase Phase 4
Start date February 2011
Completion date August 10, 2018